Skip to main content

Military Health System

DHA contributes to COVID-19 vaccine effort

Image of Vaccine bottles. A potential COVID-19 vaccine is currently in the testing stage in New Orleans, Louisiana. (Photo courtesy of Johnson & Johnson.)

Recommended Content:

Coronavirus & the MHS Response | COVID-19 Vaccine Efforts | Coronavirus and the COVID-19 Vaccine

The Department of Defense is prioritizing a joint effort to protect DOD personnel and their families by developing, distributing, and subsequently administering a Federal Drug Administration-approved vaccine to reduce COVID-19-related illnesses, hospitalizations, and deaths. This effort is critical to the strategy of helping restore societal functioning and maintain military readiness to defend the nation and its interests.

While Pfizer’s vaccine is being distributed to all U.S. jurisdictions for administration, several more candidates are in development and clinical trials continue to be conducted simultaneously with pharmaceutical partners. The Defense Health Agency’s Immunization Healthcare Division (IHD) is contributing to the investigative effort by providing study sites at military medical treatment facilities and clinical trial centers for AstraZeneca’s Phase III trials.

Following FDA’s emergency use authorization on Dec. 12 to distribute Pfizer’s vaccine, DOD initiated its planned, standardized, and coordinated strategy to prioritize, distribute, and administer its initial allocation of just under 44,000 vaccines to prioritized DOD personnel. Emergency department and Intensive Care Unit healthcare workers in 16 designated locations will receive the vaccines from this initial allotment, but the vaccination effort will extend on a rolling basis to approximately 11.1 million DOD personnel. The DOD will have an independent, but collaborative, program with the U.S. Department of Health and Human Services and the Center for Disease Control to provide COVID-19 vaccines to DOD uniformed service members, both the active and Selected Reserve components, including members of the National Guard; dependents; retirees; civilian employees, and selected DoD contract personnel as authorized in accordance with DOD regulation.

The Department’s priorities are protecting our Service members, DOD civilians, and families; safeguarding our national security capabilities; and supporting the whole-of-nation response to the COVID-19 pandemic.

Military building with sign that says "OWS Vaccine Trial Here"
The entrance to the patient testing facility of the Operation Warp Speed vaccine trial at Joint Base San Antonio-Lackland, Texas. Operation Warp Speed is a partnership to accelerate the development, manufacturing, and distribution of COVID-19 vaccines. (Photo by Airman 1st Class Melody Bordeaux/59th Medical Wing.)

The DoD will have an independent, but collaborative, program with the U.S. Department of Health and Human Services (HHS) and the Center for Disease Control (CDC) to provide COVID-19 vaccines to DoD uniformed service members, both the active and Selected Reserve components, including members of the National Guard; dependents; retirees; civilian employees, and selected DoD contract personnel as authorized in accordance with DoD regulation. The Department’s priorities are protecting our Service members, DoD civilians, and families; safeguarding our national security capabilities; and supporting the whole-of-nation response to the COVID-19 pandemic.

Dr. Limone Collins, Jr., chief of vaccine safety and evaluation at IHD, talked to MHS about the development and clinical trials process of the vaccines.

MHS: What role has IHD had in the COVID-19 vaccine development?

Collins: This is a collaborative effort consistent with how we do things within the DOD. It’s not just IHD – we had a contributory role, but this effort couldn’t have been accomplished without a number of folks within the DOD to make this happen. Our primary role in IHD is to serve as consultants and guides to immunizations within the DOD based on our knowledge and our familiarity with respective points of contact, the variety of military medical treatment facilities, and the procedure itself. It was based on our experience collaborating with the Infectious Disease Clinical Research Program out of the Uniformed Services University of the Health Sciences with a multi-site study looking at the effectiveness of the different types of the influenza vaccine that helped us, particularly within IHD as well as IDCRP, to really know the lay of the land and to help serve as consultants to make the DOD’s role in this even smoother.

MHS: How is a vaccine like this, to counter the SARS CoV2 virus, developed?

Collins: There are a variety of vaccine types but the primary types that have gone to EUA [emergency use authorization] are called messenger RNA [ribonucleic acid] (mRNA)-type vaccines. The DOD is involved with what is called a viral vector-based vaccine. The whole thought process is to see how we can manipulate the immune system to get the most effective vaccine. It has been taken up by a number of the manufacturers early on in the hypothesis to see what type of vaccine we are going to be looking at to try to accomplish the ultimate goal of having an effective vaccine.

MHS: How was it able to be developed so much faster than other vaccines?

Collins: There had been some research, particularly based on our experience with the Ebola vaccine and dealing with SARS [Severe Acute Respiratory Syndrome] and Ebola, so that was helpful. But there are also new constructs in regard to how we develop vaccines. The utilization of different technologies contributed to our ability to move at a more rapid rate, and the combination of the veering phases that we would generally go through also helps. It was a combination of all these things: newer technologies, looking at our past experience with similar organisms, as well as combining the typical phases that we generally go through.

MHS: How many steps/phases comprise a vaccine trial and what occurs in each?

Collins: The classic answer is that there are four phases. The first phase, which some folks call Phase 0, is when you start developing your hypothesis: What type of vaccine are we looking at? And that’s when you consider whether we’re going to have an inactivated vaccine, use the mRNA technology, or a viral-vector vaccine? What are we looking to accomplish with the vaccine we’re proposing? That is followed by looking at a smaller group of individuals, generally less than 100 healthy folks, to look at the safety of the particular vaccine. Then you go to the next step (Phase II), where you have a larger group of individuals, again looking at the safety and the effectiveness. Then you get to where most of the vaccine trials currently stand, which is Phase III, where you have a large trial of individuals (within the 30,000 or 40,000 range) focusing on the efficacy of the vaccines. That is followed by Phase IV, where you’ve done your large trials, sent it to the FDA for analysis and their determination that your vaccine has met all its goals and is an efficacious as well as an effective vaccine.

What most people don’t realize is that even after you get licensing by the FDA there is a follow-up period, what we call a post-surveillance activity, which basically continues with the evaluation of a vaccine or drug, where you continue to observe them for their safety precautions. This is particularly important because now you’re putting it into the general population, so it becomes even more important to look at whatever safety signals may come when you put it into that general population.

MHS: How long is that follow-up observation period once it’s distributed among the general population?

Collins: All those things were determined by the FDA during their analysis – they make the final decision on the length of the post-surveillance time period. There could be contributory information that the Advisory Committee on Immunization Practice may also try to solicit in regard to that post-surveillance time period.

MHS: What is the process of recruiting volunteers for vaccine trials?

Collins: That’s particularly important with regard to this vaccine. A lot of it is determined by the scientists of the manufacturers in their initial proposal. It’s particularly important for the COVID-19-related vaccines based on what we’re seeing in regard to the epidemiology, what’s happening with the disease manifestations, its morbidity and mortality.

MHS: Was there any special effort to include military service members to volunteer for the trials?

Collins: All the volunteers in the AstraZeneca trials, in which the DOD is participating, are DOD beneficiaries. When the company approached the DOD, we looked at who would be captured by our variety of military medical treatment facilities, so although the initial conversation considered folks outside DOD beneficiaries, in order to really help facilitate the logistics, such as access to military facilities, it was decided that we would focus primarily on DOD beneficiaries. Trying to incorporate individuals who didn’t have that usual access to our facilities or to onboarding our clinics, etc. would have been a bridge too far, particularly when considering the time frame we had, so that’s why it was limited to military service members.

MHS: When people hear in the news that a vaccine candidate is at 90 or 94 percent efficacy rate, what does that mean?

Collins: To put it in simple terms, it’s a percentage of reduction in disease in the vaccinated group versus or compared to those who are unvaccinated.

You have different arms: Individuals who were vaccinated with the product and individuals who were given a placebo. But it’s blinded, so neither the individuals nor the investigators know whether a particular volunteer is getting the vaccine or a placebo. Then, the individuals from both arms go out into their environment where there’s a potential for them to be exposed to COVID-19. The investigators then look at the number of people from the vaccinated group who got COVID-19 versus the number from the group that received the placebo that got COVID-19. For example, out of 100 people who were vaccinated maybe five got COVID-19 versus the group of 100 folks who got the placebo of which maybe 50 developed COVID-19. That’s how you do your comparison and arrive at the efficacy rates.

MHS: Does getting a vaccine prevent the person from contracting the disease, or does it cause their symptoms to be less severe if they get it, or both?

Collins: Now you understand precisely the importance of why we need multiple vaccines, because they work differently. It’s also why we need to continue to observe what occurs with each individual vaccine and the epidemiology.

What we think may happen is some of the vaccines may do more mitigating. For example, if you take a flu shot you may contract the virus, but abort the symptoms, that is, you may have milder symptoms such as fever or nasal congestion. In that circumstance, you mitigated some of the sequelae or symptoms associated with influenza the disease. That’s what we’ve seen periodically with utilizing a variety of the influenza vaccine, particularly. There are years where we have “better” flu years or seasons than others; that’s because the development of the influenza vaccine for that year did more mitigation than eliminating the disease.

You also may be interested in...

Military Medical Officials Back FY 23 Budget Before Senate Appropriations Committee

Article
4/6/2022
Marines with Marine Wing Headquarters Squadron, 3rd Marine Aircraft Wing take precautionary measures by cleaning and disinfecting their hands during field day on Marine Corps Air Station Miramar, Calif., March 20, 2020, to mitigate the spread of COVID-19 while continuing to perform mission-essential tasks. (Photo: Marine Corps Lance Cpl. Jaime Reyes)

Military Medical officials, including Army Lt. Gen. (Dr.) Ronald J. Place, Defense Health Agency director, back FY 23 Budget before the Senate Appropriations Committee, March 29, 2022.

Recommended Content:

Public Health | Coronavirus & the MHS Response

How COVID-19 Made the Military Medical Community Stronger

Article
3/21/2022
Image of a service member being treated

Lessons learned from the COVID-19 pandemic has made the military medical community stronger and will help when confronting the next crisis, whether that’s another pandemic, a new conflict or natural disaster

Recommended Content:

Health Readiness & Combat Support | Coronavirus and the COVID-19 Vaccine | Coronavirus & the MHS Response

COVID-19 Responses Underscore Importance of Patient Safety

Article
3/14/2022
Every day, patient safety is one of the top priorities for the Defense Health Agency. Patient safety means providing ready, reliable care to service members, veterans, and dependents no matter the circumstances. (Photo: Defense Health Agency)

Patient safety is a topmost concern of MHS, and Patient Safety Awareness Week 2022 focuses on Ready, Reliable Care.

Recommended Content:

Patient Safety | Patient Safety Awareness Week | Coronavirus and the COVID-19 Vaccine | Coronavirus & the MHS Response | Patient Safety Awareness Week

Answering Your Questions About COVID-19 Testing

Article
2/25/2022
Military personnel performing a COVID-19 Test

COVID-19 continues to spread, now as the Omicron variant. Getting vaccinated is the most effective way to protect you and your family from getting seriously ill, getting hospitalized, or dying. You should also make sure you’re up to date with your vaccines. Testing is another important step you can take to protect yourself and others.

Recommended Content:

Coronavirus and the COVID-19 Vaccine | Coronavirus & the MHS Response | At-Home COVID-19 Tests

Defense Department Announces Distribution of COVID-19 Tests for Military Beneficiaries

Article
2/25/2022
A Soldier assigned to the Connecticut National Guard helps load a shipment of at-home COVID-19 testing kits into a truck at a regional distribution point in North Haven, Connecticut, Jan. 3, 2022. These kits were picked up by representatives from local towns and municipalities to be handed out to their communities.

The Department of Defense will offer at-home COVID-19 tests for military beneficiaries at military hospitals or clinics, on a supply available basis, in the coming weeks.

Recommended Content:

Coronavirus and the COVID-19 Vaccine | At-Home COVID-19 Tests | Coronavirus & the MHS Response

Military Medical Units Support Civilian Hospitals Strained By COVID-19 Surge

Article
2/14/2022
Air Force Staff Sgt. Bradley Gorman, a medical technician assigned to a military medical team deployed to Yuma, Arizona performs a nasal swab at the Yuma Regional Medical Center’s COVID testing drive-thru in Yuma, Jan. 17, 2022.

Thousands of service members have been supporting civilian hospitals with testing, vaccinations and treatment of seriously ill patients.

Recommended Content:

Coronavirus & the MHS Response

Do You Have COVID-19? Influenza? Or is it RSV? Here’s What to Look For

Article
1/24/2022
Military personnel preparing a COVID-19 test sample for processing

Knowing the symptoms of COVID-19/RSV/Flu will help your medical treatment

Recommended Content:

Coronavirus and the COVID-19 Vaccine | Seasonal Influenza Vaccine Toolkit | Coronavirus & the MHS Response | Medical and Dental Preventive Care Fitness | Children's Health

Medical Leaders Address COVID-19 Concerns During Family Forum

Article
1/21/2022
Navy Petty Officer 3rd Class Jemuel Macabali, from San Diego, Calif., gives the COVID-19 vaccine to staff at Camp Lemonnier, in Djibouti, Aug. 13, 2021.

Top health leaders talk about the recent spike in COVID-19 infections and the impact on the military community.

Recommended Content:

Coronavirus & the MHS Response

Critically ill COVID Patient Delivers Baby While on Heart-Lung Bypass

Article
1/11/2022
Retired U.S. Marine Corps Gunnery Sgt. Carlos Hernandez and his wife, Ashley, take a family portrait with their six children. Ashley is BAMC’s first patient to give birth while on Extracorporeal Membrane Oxygenation.

Hernandez, a Marine Corps spouse and mother of five, is BAMC’s first patient to give birth while on Extracorporeal Membrane Oxygenation.

Recommended Content:

Women's Health | Coronavirus & the MHS Response

Development of WRAIR’s Pan-Coronavirus Vaccine Shows Promise

Article
12/28/2021
A vial of spike ferritin nanoparticle WRAIR's COVID-19 vaccine

Series of preclinical studies supports the Army’s pan-coronavirus vaccine development strategy

Recommended Content:

Coronavirus and the COVID-19 Vaccine | Coronavirus & the MHS Response | COVID-19 Vaccine Efforts

Immunization Experts are Central to COVID-19 Vaccine Program

Article
12/20/2021
Medical director at Fort Riley, Kansas receives a COVID-19 vaccination In his left arm from a tech in personal protective equipment.

Immunization Health Division at forefront of COVID-19 vaccinations.

Recommended Content:

Coronavirus & the MHS Response | COVID-19 Vaccine Efforts | Coronavirus and the COVID-19 Vaccine

Military Health System Marks 1-Year Anniversary for COVID Vaccinations

Article
12/14/2021
FEmale Marine gets COVID 19 vaccination in left  arm at Camp LeJeune in December 2020

More than 6.4 million COVID-19 vaccine doses have been administered a year after first shots within MHS.

Recommended Content:

Coronavirus & the MHS Response | COVID-19 Vaccine Efforts | COVID-19 Vaccine Efforts | Coronavirus and the COVID-19 Vaccine

MHS Reaches 6 Million Doses of Vaccine Against COVID

Article
11/10/2021
Airmen of the 139th Airlift Wing, Missouri Air National Guard, receive COVID-19 immunizations as a part of the federal mandate at Rosecrans Air National Guard Base, St. Joseph, Missouri, Oct. 2, 2021. The 139th Medical Group oversees the operation. .

Military passes 6 million mark for COVID-19 shots administered across the Military Health System.

Recommended Content:

Health Readiness & Combat Support | Coronavirus & the MHS Response | COVID-19 Vaccine Efforts | COVID-19 Vaccine Efforts | COVID-19 Information for Military Treatment Facility Directors

COVID 19 Vaccine Is Now Available for Children 5 to 11

Article
11/9/2021
5-year-old girl in mask reads a book by herself

COVID-19 vaccines for 5-11 year olds are ready now through MHS

Recommended Content:

Coronavirus & the MHS Response | COVID-19 Vaccine Efforts | COVID-19 Vaccine Efforts

Pregnancy Health Alert: COVID-19 Vaccine is Strongly Recommended

Article
10/20/2021
Pregnant women gets the COVID-19 vaccine

Get vaccinated for COVID-19 if you’re pregnant or trying, DOD and CDC and advise.

Recommended Content:

Coronavirus and the COVID-19 Vaccine | Women's Health
<< < 1 2 3 4 5  ... > >> 
Showing results 16 - 30 Page 2 of 14
Refine your search
Last Updated: September 27, 2022
Follow us on Instagram Follow us on LinkedIn Follow us on Facebook Follow us on Twitter Follow us on YouTube Sign up on GovDelivery